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Objectives: The New Medicine Service (NMS) is a national community pharmacy 
service to support medicines-taking in people starting a new medicine for defined 
long-term conditions. The study investigated the expansion of NMS for patients with 
gout newly prescribed allopurinol as urate lowering therapy(ULT). Non-adherence 
with ULT is > 60% in the UK MethOds: A probabilistic cost-effectiveness analysis 
from a NHS perspective was conducted to compare NMS (two follow-up consul-
tations to identify and resolve medicines problems) with standard practice (SP) 
(usual supply without further follow-up).Treatment success was defined as patients 
reaching serum-uric-acid-levels < 6mg/dL (sUA-controlled). A Markov model was 
developed to generate incremental cost-effectiveness ratios (ICER). Three health-
states were included: sUA-controlled; sUA-uncontrolled; death. sUA-uncontrolled is 
associated with more acute gout attacks, higher mortality and is more likely in non-
adherent patients. Cycle length was 1 year with a life-time horizon. Transition prob-
abilities, resource use and utilities were derived from published studies. Costs and 
utilities were discounted at 3.5%. The results were plotted on an ICER-scatter-plane 
and presented as a cost-effectiveness acceptability curve (CEAC). Results: mean 
(95% CI) cost per patient- NMS: £2569.43 (2203.69, 2935.17); SP: £2595.39 (2229.63, 
2961.14) and mean (95% CI) QALYs generated per patient- NMS: 10.39 (10.10, 10.68) 
SP: 10.34(10.06,10.60) suggested that NMS dominated SP with increased QALYs (0.058 
(-0.0008, 0.1168)) and reduced costs (-£25.96 (-81.37, 29.44). There was a 83.3% prob-
ability that NMS dominated SP and 98.4% probability that NMS was cost-effective 
at £20000 per QALY ceiling willingness-to-pay. cOnclusiOns: NMS appears to be 
cost-effective when initiating ULT. It was assumed NMS would increase ULT adher-
ence by 11% as in other diseases. NMS remained dominant down to an adherence 
increase of 5.4%. Reasons for ULT nonadherence matched the intervention design 
but further work is needed to assess the actual effectiveness of NMS in ULT.
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bAckgROund: Compliance to therapy is a widespread public health concern espe-
cially for chronic diseases, such as osteoporosis, as it is associated with increased 
morbidity and mortality due to fragility fractures. Objectives: To conduct the sys-
tematic review of clinical trials evaluating adherence to oral and parenteral bispho-
sphonates in patients with postmenopausal and senile osteoporosis. MethOds: 
We searched publications in PubMed and the Cochrane Library in November 2014. 
Studies of any design published in English were considered. The following criteria 
of medication adherence were taken into account: persistence rate (percentage 
of patients remaining on therapy at a given time). compliance rate (percentage 
of patients act in accordance with the prescribed interval and dose of a dosing 
regimen), medication possession ratio (proportion of doses dispensed in relation 
to doses prescribed), persistence (number of days from initiation to discontinuation 
of therapy). Results: Thirty one publications were included (1 meta-analysis, 5 
systematic reviews, 14 RCT, 7 prospective cohort studies, and 4 retrospective cohort 
studies). Original studies were heterogeneous in terms of drugs, treatment regimes, 
follow up periods, and measurements of adherence, so quantitative meta-analysis 
was not possible. The 12 months persistence rate for patients receiving oral bis-
phosphonates varies in the range of 16-78% in real practice and 54-88% in RCT. The 
persistence rate for parenteral bisphosphonates at 12 months was 86% in one real 
practice study, and 95% in one RCT. cOnclusiOns: Methodology of evaluating 
compliance/adherence or persistence is heterogeneous among the studies of bis-
phosphonates treatment in patients with osteoporosis. Сompliance and persistence 
with bisphosphonates are poor and suboptimal in real practice. The parenteral 
administration of bisphosphonates seems to have enhanced adherence when com-
pared with oral bisphosphonates.
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Objectives: To describe treatment discontinuation among postmenopausal 
women initiating denosumab or monthly oBPs in routine clinical practice in 
Bulgaria. MethOds: This retrospective chart review, conducted in 12 Bulgarian 
endocrinology or rheumatology practices, included postmenopausal women ≥ 50 
years old initiating denosumab or monthly oBPs between 1-Oct-2011 and 30-Sep-
2012, followed up to 24 months after treatment initiation. For both denosumab and 
monthly oBPs, discontinuation date was taken from the patients’ medical records 
(including any switch to another treatment/dosing regimen). If no such date was 
recorded, patients’ were assumed to have continued on treatment. Denosumab per-
sistence at 12, 18 and 24 months was defined as receiving the subsequent injection 6 
months +60-days after the previous injection. Persistence to monthly oBPs could not 
be calculated. Results: A total of 224 women initiating denosumab and 217 initiat-
ing monthly oBPs met the inclusion criteria. Of these, 57 (25%) initiating denosumab 
and 38 (18%) initiating monthly oBPs had experienced ≥ 1 prior OP fracture; 3 (1.3%) 
initiating denosumab and 8 (3.7%) initiating monthly oBPs experienced ≥ 1 OP fracture 
during the follow-up period. At treatment initiation, mean (SD) BMD T-scores for the 
denosumab and oBPs groups were -3.2 (±0.65) and -3.0 (±0.57) at the lumbar spine, -3.2 
(±0.69) and -2.8 (±0.73) at the total hip and -2.6 (±0.71) and -2.4 (±0.77) at the femoral 
neck. Within the 24-month follow-up, 4.5% of women initiating denosumab and 56.2% 
initiating monthly oBPs discontinued treatment; median (interquartile range) time 
to discontinuation, 729.0 (728.3„Ÿ729.0) and 367.0 (354.0„Ÿ484.8) days, respectively. 
Denosumab persistence was 100%, 99.1% and 98.7% at 12, 18 and 24 months, respec-
between the first and second courses to 23.9 weeks between the sixth and seventh 
courses. Subgroup analyses performed in 115 patients receiving rituximab in line 
with National Institute for Health and Care Excellence (NICE) guidance, i.e. after 
prior biologic therapy, demonstrated that dispensing frequency in this group did 
not differ markedly from the whole cohort. cOnclusiOns: The findings of this 
analysis show that long-term rituximab use in the National Health Service differs 
from that assumed by NICE in previous appraisals of biologics in RA, with possible 
implications for future assessments of cost-effectiveness.
MuSculaR-Skeletal diSoRdeRS – Patient-Reported outcomes & Patient 
Preference Studies
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Objectives: To determine 12-month persistency rates for five commonly-used 
anti-inflammatory biologic agents and identify cost and patient characteristics 
associated with persistency. MethOds: Using an administrative claims database 
for > 30 U.S. commercial health plans (9.2 million members), we identified patients 
aged ≥ 18 years who had ≥ 1 claim for a biologic anti-inflammatory agent (tocili-
zumab, certolizumab pegol, etanercept, adalimumab or infliximab) in 2012 or 2013 
and were continuously enrolled for ≥ 15 months after the initial claim date. We 
determined rates of 12-month persistency overall and by drug, diagnostic indication, 
comorbidity count, route of drug administration, and copayment level. Results: 
A total of 15,834 patients met study criteria. Twelve-month persistency rates were 
70.7% among all patients and 51.5% among patients new to therapy. Persistency was 
highest for infliximab (82.3%), followed by adalimumab (66.1%), certolizumab pegol 
(65.5%), etanercept (65.1%), and tocilizumab (60.6%) (P< 0.001). Higher persistency 
was observed for drugs administered intravenously (81.2%) versus subcutaneously 
(65.6%) (P< 0.01). Persistency was higher in patients with Crohn’s disease/ulcera-
tive colitis (79.1%) than in patients with rheumatoid arthritis (67.0%) or psoriatic 
conditions (61.4%) (P< 0.01) and was also higher in patients with no comorbidities 
than in those with 1 or ≥ 2 (P< 0.01). Highest persistency was observed for patients 
with a mean plan copayment of $50 to < $100, followed by $0 to< $50, $100 to < $300, 
and ≥ $300 (P< 0.01). This trend was observed irrespective of intravenous or subcu-
taneous route of administration. cOnclusiOns: Twelve-month persistency with 
anti-inflammatory biologic agents was highest in patients with Crohn’s disease 
and lower in patients new to therapy and in those with comorbidities. Persistency 
was higher for drugs administered intravenously versus subcutaneously. Although 
the relationship between persistency and cost-sharing was not linear, copayments 
≥ $300 were associated with lowest persistency. Patient and plan characteristics 
should be considered in efforts to improve patient adherence to therapy.
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Objectives: Non-adherence to treatment represents an important public health 
problem. Little is known about the frequency with which patients fail to fill initial 
prescriptions (“primary non-adherence”) and its predictors. Our aim was to esti-
mate primary non-adherence to antiosteoporotic treatment and its associated fac-
tors. MethOds: Prospective cohort study comprising men and women ≥ 50 years 
(ESOSVAL cohort) who started antiosteoporotic treatment between 2009 and 2011. 
Data were obtained by linking diverse electronic health records of the Valencia region, 
which allows the differentiation between prescriptions (what the doctor prescribed) 
and dispensing (what the patient fills from the pharmacy) at individual level. A 
descriptive analysis was performed according to primary non-adherence and a mul-
tivariable logistic regression analysis to assess factors associated (patient characteris-
tics and medication related covariates) with primary non-adherence. Results: From 
2260 treated patients of the ESOSVAL cohort 712 (31.5%) were new users. Of those, 80% 
were female, mean age 65.4 (64.7-66.1), 22.3% had previous osteoporotic fracture, and 
22.2% had a 10-year risk of hip fracture ≥ 3. Most of the patients (84.1%) were treated 
with bisphosphonates. Regarding primary non-adherence, 6.5% of patients did not fill 
their first prescription at the pharmacy. These patients were more likely to be younger, 
to use medications that decrease bone mass, to have concomitant medications, to 
have high risk of hip fracture (assessed by FRAX), and hospitalizations in the last year. 
Factors independently associated with primary non-adherence were being over 65 
years old (OR:0.29; CI95%:0.13;0.64) compared to the 50-65 year-old age stratum and 
polypharmacy (OR:0.45; CI95%: 0.24;0.86). cOnclusiOns: Primary non-adherence 
was substantial although lower than that observed in other therapeutic areas. Very 
few characteristics were independently associated with primary non-adherence. Our 
findings suggest that those at higher risk for osteoporotic fracture and older were 
more likely to be non-adherent. Further research is needed regarding primary non-
adherence predictors.
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yet. Taking into consideration the variety of HRQoL tools and data available, more 
options could be explored to identify the most sensitive utility approach.
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Objectives: The enormous socioeconomic impact of rheumatoid diseases has 
been increasingly studied in the USA and Europe. The objective of this study is to 
determine the burden of RA in Russia, focusing on outcomes such as health-related 
quality of life (QoL: EQ-5D, HAQ-DI), work productivity (WPAI) and use of health-
care resources (healthcare provider, hospital and emergency visits). MethOds: A 
cross-sectional cohort of 408 adult patients with a diagnosis of RA for at least 12 
months were recruited in 2013-2014 by 51 rheumatologists, in Moscow and 12 other 
Russian regions. Patients with concomitant Crohn’s disease, psoriasis or other forms 
of arthritis were excluded. Subjects underwent an assessment of their RA status 
(previous 12 months to current). General linear models predicted outcomes while 
controlling for main predictors (current treatment, region, current disease activity 
– DAS28) and covariates (sociodemographics, RA activity in past week). Results: 
Most patients were female (78%), recruited in Moscow (43%) and followed by public 
hospitals (90%). Half were at radiologic stage II, overweight, at functional class 2 
and with an invalidity pension; 74% had moderate and 22% severe disease activity 
(DAS28). Current EQ-5D and HAQ-DI scores showed significant impairment (0.6, 
1.4); patients reported on average 15% absenteeism, 21% presenteeism, 24% over-
all work impairment and 49% activity impairment; over the past 12 months, on 
average they visited a rheumatologist 6 times, 17% were hospitalised and 2% had 
emergency visits. While patients in Moscow reported lower QoL, they also had lower 
absenteeism and resource use. RA activity in past week was strongly associated with 
all outcomes. cOnclusiOns: The majority of Russian RA patients had moderate 
activity and poor outcomes. While there was no significant difference in private vs. 
public hospitals, Moscow patients reported lower absenteeism and resource use 
than the other regions combined.
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Objectives: Gout is often overlooked despite the pain caused by acute flares and 
the joint damage caused by the development of debilitating tophi (deposits of uric 
acid crystals). The study objective was to review and summarise the current evi-
dence of the disease burden of chronic gout, in relation to health-related quality of 
life (HRQL), and to identify key factors correlated with an increased disease burden. 
Our primary aim was to support the economic evaluation of new treatments for 
gout. In addition, we identified key data gaps that may need further investiga-
tion. MethOds: A systematic literature review was conducted using the MEDLINE 
database and The Cochrane Library. Articles published in English between January 
2000 and July 2014 that reported the humanistic burden (HRQL and/or utility) of gout 
were identified. Key data were extracted and summarised, with key themes and data 
gaps identified. Results: Searches identified 323 studies, of which 21 were relevant 
to the humanistic burden of gout. The humanistic burden was largely due to physical 
disability and pain resulting from chronic clinical manifestations. Utility weights, 
as assessed by Short Form 6 dimensions, were estimated at 0.53 for a patient with 
severe gout (3+ flares/year and tophi) and 0.73 for an asymptomatic patient with 
serum uric acid levels < 6mg/dL. cOnclusiOns: The evidence confirms that gout 
represents a significant burden in terms of HRQL. A reported growing prevalence 
means this is likely to be of considerable concern for healthcare decision makers. 
In light of this, effective urate-lowering treatments are likely to be valued, if they 
can be clearly demonstrated to be both clinically effective and cost effective. There 
is a need to develop a comprehensive set of comparative HRQL utility assessments, 
especially in non-US countries.
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Objectives: The aim of this study was to investigate the socio-economic impact of 
chronic autoimmune diseases, mainly rheumatoid arthritis (RA) and work disabilities, 
among patients in Slovakia. MethOds: Patients were prospectively recruited in the 
National Institute for Rheumatic Diseases in 2014 – 2015 and the data were collected 
through specifically designed questionnaire. Research was prepared and consulted 
with relevant patient organization League against Rheumatism in Slovakia. Results: 
The sample (200 respondents) was predominantly female (57%) with diagnosis of 
RA (66%) followed by ankylosing spondylitis (17%). As many as 65% of the patients 
became permanently work disabled at the average age of 41, with full work disability 
being more common (36%) than partial disability (30%). The occurrence of sick leaves 
within preceding 12 months among actively working was 52% with an average length 
of 51 days. Three most frequently reported areas negatively affected by the disease: 
social activities (reported by 65% respondents), professional career (53%) and quality 
of a relationship with their partner (25%). Twenty-five percent of respondents had to 
change their jobs due to the disease. Average personal expenses of the treatment in 
the preceding 3 months were 76€ , traveling costs in the first place. Despite disease 
stabilization in the sample majority, 70% of respondents stated restrictive (51%) or 
very restrictive (19%) impact of the disease on their overall functioning. In the preced-
ing week, strenuous activities and sports became the most limited. The support from 
tively. cOnclusiOns: In this study of routine clinical practice in Bulgaria, only 4.5% 
of women initiating denosumab discontinued treatment within 24 months, compared 
with more than half of those initiating monthly oBPs.
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Objectives: Many studies prove non-compliance to medication to be one of the 
biggest problems in health care today. Non-compliance can lead to increased cost 
of care due to additional hospitalizations, emergency care, medication. These facts 
are relevant for patients with arthritis as the effects of non-compliance can increase 
the risk of acute crisis, pain and sick pays. Our objective was to examine the fac-
tors that can lead to non-compliance among patients with arthritis. MethOds: The 
Morisky 8-item Medication Adherence Questionnaire was applied to 96 patients with 
arthritis. After the ranking of the patients to the three groups – with low adherence, 
with medium adherence and with high adherence, those that were in the first group 
were asked about the factors that make them not compliant with the medication. 
The factors were grouped into two groups – subjective (expensive treatment, forget-
ting to take medication, difficulties to follow the regimen, etc.) and objective (ADRs, 
difficulties with the package, difficulties to find the prescribed medication in the 
pharmacy, etc.) Results: Thirty-one per cent were scored with low adherence, vary-
ing from 3 to 8 relevant to complete failure to take the prescribed drugs. The factors 
that were outlined were mainly objective – 52% - ADRs; 49% - difficulties to open the 
package. From the subjective factors 15% from the respondents rank the treatment as 
expensive and they answer that they cannot afford it to purchase the prescribed treat-
ment. cOnclusiOns: Drug treatment does not appear to be a significant problem in 
management of arthritis, as over 69 % of the patients were taking their medications 
all or most of the time. However the subjective factors can be demotivating for the 
patients and they have to be taken in mind during the patients’ consultation by the 
health care providers in order to be increased the rate of compliance.
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Objectives: Quality of life weights (utilities) are requested by many decision mak-
ers. In rare diseases the reliance on very small single arm trials makes it almost 
impossible to sensibly aggregate health-related quality of life (HRQL) data. This study 
presents a case study in hypophosphatasia (HPP), an ultra-rare disease, where two 
different methods were used to estimate utilities. MethOds: Study 1: Detailed case 
histories were developed which described the functional, symptom and HRQL burden 
for hypothetical patients with HPP (adults and children) through interviews with 
clinical experts (n= 6). Seven case histories, defined by predicted 6 minute walk test 
(6MWT) for those aged 5+ and the need for invasive ventilation for infants, were 
then assessed by experts (n = 9) using EQ-5D-5L. Study 2: A survey of patients with 
HPP and parents recruited through advocacy groups asked people to assess HRQL by 
EQ-5D-3L and also to report on mobility (as a proxy for the 6MWT). No infant states 
were included in study 2. Results: Study 1: Development of the case histories was 
challenging because of the experts’ unfamiliarity with 6MWT in clinical practice and 
their limited exposure to the possible broad range of patient severity. EQ-5D utilities 
were: infants < 5 on invasive ventilation = -0.09, no ventilation= 0.24; children/adults 
ranged from 0.86 (> 82% 6MWT) to 0.23 (< 46% 6MWT). Study 2: children’s (n= 9 parents) 
EQ-5D scores ranged from 0.79 (> 82% 6MWT) to -0.24 (< 46% 6MWT); and adults (n= 25) 
ranged from 0.51 (> 82% 6MWT) to -0.01 (< 46% 6MWT). cOnclusiOns: Two separate 
studies describe the HRQL impact of HPP in adults and children. Utility values reported 
by patients and parents were consistently lower than those reported by experts. Both 
studies have important limitations, including the sample size. On a practical level the 
QALY based system does not seem so well suited to decisions regarding orphan drugs.
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Objectives: Identification and review of used methods to derive patient utilities 
for health economic modelling in psoriatic arthritis (PsA) and ankylosing spon-
dylitis (AS) MethOds: A literature search of Embase, MEDLINE from 1996-2015 
was conducted to identify health economic, clinical studies that hold information 
about deriving utilities in PsA, AS. Additionally HTA submissions in PsA, AS were 
also screened. Publication inclusion was limited to in English language, biological 
therapy in PsA or AS. Results: In total the search retrieved 3,175 articles, of which 
124 fulfilled screening criteria. Most of the publications were screened for AS (n= 73), 
followed by PsA (n= 46) while five publications included both indications. Across 
studies baseline characteristics varied in age (Years, PsA: 35.5–65.0; AS: 24.4–61.0), 
disease duration (Years, AS: 0.7–30.2; PsA: 1.7–22.2) and gender distribution (Females, 
AS: 0–70%, PsA: 25–88%). No study was identified that used direct methods like time 
trade-off or standard gamble for utility derivation. Among generic measures SF-36 
(n= 27 for PsA, n= 55 for AS), EQ-5D (n= 10 PsA, n= 14 AS) were primarily used. In total 
45 different disease specific tools were identified (PsA, n= 30; AS, n= 15). The HAQ-DI 
(n= 36) and ASQoL (n= 21) were the most common tools in PsA, AS respectively. 
Among the cost-effectiveness studies 13 utility derivation algorithms in PsA and 
5 in AS were identified. EQ-5D was the most commonly used HRQoL instrument 
to derive utilities (PsA, n= 9; AS, n= 3). Most cost-effectiveness models used HAQ-DI 
in PsA while BASFI, BASDAI were used in AS to derive utilities. cOnclusiOns: 
Even though more publications were identified in AS, more utility derivation algo-
rithms were identified in PsA. However no standard process has been established 
